# The Medicines (Applications for Grant of Product Licences—Products for Human Use) Regulations 1993, Paragraph 9


A summary of the product characteristics which shall contain the following information:
(a) the name of the product;
(b) its qualitative and quantitative composition in terms of the active ingredients, knowledge of which is essential for proper administration of the product, using international non-proprietary names or, where there is no such name, the usual common name or chemical description;
(c) its pharmaceutical form;
(d) clinical particulars covering—
(i) therapeutic indications,
(ii) posology and method of administration for adults and, where necessary, for children,
(iii) contra-indications,
(iv) special warnings,
(v) special precautions for use and, in relation to any immunological medicinal product to which Directive 89/342/EEC applies, information regarding any special precautions to be taken by persons handling the product and persons administering it to patients, together with any precautions to be taken by the patient,
(vi) interaction with other medicaments and other forms of interaction,
(vii) use during pregnancy and lactation,
(viii) effects on ability to drive and to use machines,
(ix) undesirable effects (including their frequency and seriousness),
(x) overdose (covering symptoms, emergency procedures and antidotes);
(e) its pharmacological properties and, insofar as this information is useful for therapeutic purposes, pharmacokinetic particulars;
(f) pharmaceutical particulars covering—
(i) qualitative composition in terms of the excipients used,
(ii) major incompatibilities,
(iii) shelf-life, when necessary after reconstitution of the product or when the container is opened for the first time,
(iv) special precautions for storage,
(v) nature and composition of the container,
(vi) special precautions for disposal of unused products or waste materials derived from such products, if appropriate,
(vii) name or style and permanent address or registered place of business of the holder of the licence;
(g) in relation to any radiopharmaceutical to which Directive 89/343/EEC applies—
(i) full details of internal radiation dosimetry, and
(ii) additional detailed instructions for extemporaneous preparation and quality control of such preparation and, where appropriate, maximum storage time during which any intermediate preparation such as an eluate or the ready to use pharmaceutical will conform with its specifications; and
(h) in relation to any indications to which sub-paragraphs (a) and (b) of paragraph 22 below apply, a statement drawing the attention of persons qualified to prescribe or supply the product to the fact that the particulars available concerning the product are as yet inadequate in certain specified respects.

---
Source: https://www.legislation.gov.uk/uksi/1993/2538/schedule/1/paragraph/9 (the official version)
Page: https://openlegislation.uk/medicines-applications-for-grant-of-product-licencesproducts-for-human-use-regulations-1993/schedule-1/paragraph-9
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

